Discontinuation of odanacatib and other osteoporosis treatments: Here today and gone tomorrow?

Pharmacologic Treatment of Low Bone Density or Osteoporosis to Prevent Fractures: A Clinical Practice Guideline from the American College of Physicians

(2013) Amir Qaseem et al.   ANNALS OF INTERNAL MEDICINE

Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis

(2010) Patrick Garnero et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect

(2010) John A Eisman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Safety of Bisphosphonates in the Treatment of Osteoporosis

(2009) Robert R. Recker et al.   AMERICAN JOURNAL OF MEDICINE

Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double-Blind, Randomized, Placebo-Controlled Phase I Studies

(2009) S A Stoch et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

To stop or not to stop, that is the question

(2008) Ego Seeman   OSTEOPOROSIS INTERNATIONAL